Robert J. Motzer, MD | Authors

May 02, 2022

Brian Rini, MD, summarizes the thoughts of his colleagues on the use of lenvatinib plus pembrolizumab to treat advanced renal cell carcinoma.

May 02, 2022

A panel of oncologists look at what’s in the pipeline for advanced renal cell carcinoma, including trials and treatment options.

May 02, 2022

Two kidney cancer experts explore the current unmet needs for patients with advanced renal cell carcinoma.

May 02, 2022

Closing out their discussion on renal cell carcinoma management, experts highlight unmet needs and look toward the future treatment landscape.

May 02, 2022

Following the advent of adjuvant pembrolizumab in high-risk renal cell carcinoma, experts consider treatment strategies for patients who progress on adjuvant pembrolizumab.

April 25, 2022

Considerations for whether adjuvant pembrolizumab is the new standard of care for patients with renal cell carcinoma at intermediate or high risk of recurrence.

April 25, 2022

Expert panelists review a clinical scenario of renal cell carcinoma managed with adjuvant pembrolizumab postnephrectomy based on results of the KEYNOTE-564 trial.

April 21, 2022

A look at the current unmet needs in front-line renal cell carcinoma treatment.

April 21, 2022

Oncologists review quality of life data for patients with renal cell carcinoma receiving lenvatinib plus pembrolizumab combination treatments.

April 19, 2022

Kidney cancer experts explain how they dose lenvatinib in advanced renal cell carcinoma treatment to mitigate toxicities.